XML 59 R72.htm IDEA: XBRL DOCUMENT v2.4.0.8
16. Segment Information (Details) (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Segment Information        
Revenues $ 0 $ 0 $ 71,667 $ 374,542
Cost of sales 0 0 0 235,803
Gross margin 0 0 71,667 138,739
Deprec. & Amort 478,104 8,687 675,757 164,043
Segment profit (1,371,520) (2,092,612) (12,917,330) (11,791,869)
Operating expenses 1,371,520 2,092,612 12,988,997 11,930,608
Net loss from continuing ops. (1,380,175) (2,476,780) (2,457,949) (6,849,815)
Preferred dividends $ 0 $ 124,375 $ 171,625 $ 497,167
Net loss attributable to common shareholders (1,380,175) (2,601,155) (2,635,975) (7,366,061)
Assets 26,447,653   18,344,052 2,446,297
Liabilities 10,694,773   8,878,318 20,852,636
Bio Pharma [Member]
        
Segment Information        
Revenues         
Cost of sales         
Gross margin         
Deprec. & Amort 1,000      
Segment profit (1,000)      
Operating expenses 183,000      
Other expenses         
Impact of derivative securities         
Net loss from continuing ops. (184,000)      
Loss from discontinued ops.         
Preferred dividends         
Net loss attributable to common shareholders (184,000)      
Assets 230,000       
Liabilities 2,779,000       
ProElite [Member]
        
Segment Information        
Revenues       72 375
Cost of sales       0 236
Gross margin       72 139
Deprec. & Amort       2 2
Segment profit       70 137
Operating expenses       192 990
Other expenses      (714) 97
Impact of derivative securities       0  
Net loss from continuing ops.       592 (950)
Loss from discontinued ops.    (127,000)    
Preferred dividends       $ 0 $ 0
Net loss attributable to common shareholders    (127,000) 592 (950)
Assets 344,000 1,677,000 230 2,161
Liabilities 625,000 1,998,000 2,779 2,632
Other [Member]
        
Segment Information        
Revenues       0 0
Cost of sales       0 0
Gross margin       0 0
Deprec. & Amort 477,000 9,000 587 32
Segment profit (477,000) (9,000) (587) (32)
Operating expenses 710,000 2,084,000 12,371 9,183
Other expenses 5,000 20,000 643 1,763
Impact of derivative securities    237,000 (10,459) (6,801)
Net loss from continuing ops. (1,192,000) (2,350,000) (3,142) (4,177)
Loss from discontinued ops.          
Preferred dividends    $ 124 $ (172) $ 497
Net loss attributable to common shareholders (1,192,000) (2,474,000) (2,976) (4,693)
Assets 25,878,000 511,000 17,542 285
Liabilities 7,291,000 19,927,000 5,460 15,828
Total
        
Segment Information        
Revenues       72 375
Cost of sales       0 236
Gross margin       72 139
Deprec. & Amort 478,000 9,000 676 34
Segment profit (478,000) (9,000) (604) 105
Operating expenses 893,000 2,084,000 12,728 11,897
Other expenses 5,000 20,000 (71) 1,859
Impact of derivative securities    237,000 (10,459) (6,801)
Net loss from continuing ops. (1,376,000) (2,350,000) (2,802) (6,850)
Loss from discontinued ops.    (127,000)    
Preferred dividends    $ 124 $ (172) $ 497
Net loss attributable to common shareholders (1,376,000) (2,601,000) (2,636) (7,366)
Assets 26,452,000 2,188,000 18,344 2,446
Liabilities 10,695,000 21,925,000 8,878 20,853
Stratus Rewards [Member]
        
Segment Information        
Revenues      0 0
Cost of sales      0 0
Gross margin      0 0
Deprec. & Amort      0 0
Segment profit      0 0
Operating expenses      85 1,724
Other expenses      0 0
Impact of derivative securities      0  
Net loss from continuing ops.      (85) (1,724)
Loss from discontinued ops.         
Preferred dividends      $ 0 $ 0
Net loss attributable to common shareholders      (85) (1,724)
Assets     0 0
Liabilities     $ 52 $ 122